Showing results (131-140 of 218) with videos related to
Sort By:
Pageof 22
Plos Medicine|May 30, 2017
Contribution of systemic and somatic factors to clinical response and resistance to PD-L1 blockade in urothelial cancer: An exploratory multi-omic analysisAlexandra Snyder, Tavi Nathanson, Samuel A Funt, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 9, 2022
Deciphering radiological stable disease to immune checkpoint inhibitorsJ Luo, S Wu, H Rizvi, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 10, 2021
Immunotherapy-Mediated Thyroid Dysfunction: Genetic Risk and Impact on Outcomes with PD-1 Blockade in Non-Small Cell Lung CancerJia Luo, Victoria L Martucci, Zoe Quandt, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 11, 2016
Next-Generation Sequencing of Pulmonary Large Cell Neuroendocrine Carcinoma Reveals Small Cell Carcinoma-like and Non-Small Cell Carcinoma-like SubsetsNatasha Rekhtman, Maria C Pietanza, Matthew D Hellmann, et al.Cancer Chemotherapy and Pharmacology|July 2, 2013
Risk of hemoptysis in patients with resected squamous cell and other high-risk lung cancers treated with adjuvant bevacizumabMatthew D Hellmann, Jamie E Chaft, Valerie Rusch, et al.The Oncologist|August 17, 2023
Outcomes of Combination Platinum-Doublet Chemotherapy and Anti-PD(L)-1 Blockade in KRASG12C-Mutant Non-Small Cell Lung CancerArielle Elkrief, Biagio Riccuiti, Joao V Alessi, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 28, 2016
Systematic evaluation of pembrolizumab dosing in patients with advanced non-small-cell lung cancerM Chatterjee, D C Turner, E Felip, et al.Journal for Immunotherapy of Cancer|July 24, 2023
Efficacy of PD-(L)1 blockade monotherapy compared with PD-(L)1 blockade plus chemotherapy in first-line PD-L1-positive advanced lung adenocarcinomas: a cohort studyArielle Elkrief, Joao M Victor Alessi, Biagio Ricciuti, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 23, 2019
Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expressionE J Aguilar, B Ricciuti, J F Gainor, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 29, 2022
Systemic and Oligo-Acquired Resistance to PD-(L)1 Blockade in Lung CancerAdam J Schoenfeld, Hira A Rizvi, Danish Memon, et al.Pageof 22